AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35010998
Drug: Dihydroberberine 200
RxNorm normalized name: Dihydroberberine 200 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroberberine 200 mg (D200)
Trial: 35010998
Drug: Berberine 500
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine 500 mg (B500)
Trial: 36379612
Drug: Two-stage regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage regional citrate anticoagulation (RCA) with 0.04 g/mL sodium citrate infusion for 3 hours during dialysis
Trial: 33413942
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium chloride (CaCl2) injection (2 ml of 5%) into the major atrial ganglionated plexi during CABG
Trial: 33413942
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (0.9%) injection (sham control) into the major atrial ganglionated plexi during CABG
Trial: 33413942
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium chloride (CaCl2) injection
Trial: 34545949
Drug: Luseogliflozin (SGLT2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin (SGLT2 inhibitor)
Trial: 32483061
Drug: Eccentric training
RxNorm normalized name: SYRINGE 60ML ECCENTRIC TIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eccentric training (twice-weekly for 6 weeks)
Trial: 32460786
Drug: ARCHES intervention
RxNorm normalized name: arched swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARCHES intervention (treatment condition)
Trial: 32384205
Drug: 577-nm high-power
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 577-nm high-power optically pumped semiconductor laser (HOPSL) treatment
Trial: 34032204
Drug: Daclatasvir hydrochloride
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir hydrochloride tablets (60 mg) under fasting conditions
Trial: 34032204
Drug: Daclatasvir hydrochloride
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir hydrochloride tablets (60 mg) under postprandial conditions
Trial: 33536253
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin only (Control)
Trial: 35690997
Drug: AH8 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH8 10% lotion formulated in Cetaphil Moisturizing Facial Lotion
Trial: 35643956
Drug: ORAL Surveillance
RxNorm normalized name: LANCET,SURGILANCE SAFETY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORAL Surveillance trial
Trial: 32665999
Drug: Alpha-adrenoreceptor blocker
RxNorm normalized name: Alpha-adrenoreceptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-adrenoreceptor blocker only (Control)
Trial: 35366393
Drug: Combined social
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined social communication therapy at home and in education
Trial: 32508977
Drug: Disposable infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disposable infusion needles with a separation‐free safety tube
Trial: 32508977
Drug: Conventional infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional infusion needles
Trial: 32197911
Drug: Tian‐Tian 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tian‐Tian 120 outdoor program (120 minutes outdoors daily)
Trial: 33720069
Drug: Nivolumab added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab added to first-line chemotherapy
Trial: 33720069
Drug: Pembrolizumab added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab added to first-line chemotherapy
Trial: 35149701
Drug: Gabapentin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300 mg oral) and Methylprednisolone (125 mg IV)
Trial: 34935050
Drug: Self-administered electrotherapy
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered electrotherapy treatment using the Exopulse Mollii Suit®
Trial: 36327101
Drug: Netarsudil twice
RxNorm normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Netarsudil twice a day (BID)
Trial: 32595142
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL 0.25% ropivacaine divided into four injections (two for TAP and two for RS block)
Trial: 32577745
Drug: Placebo (mock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mock titration)
Trial: 36286602
Drug: Zolmitriptan nasal
RxNorm normalized name: Zolmitriptan Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan nasal spray (ZNS) high dose
Trial: 34986394
Drug: Heparin (control)
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin (control)
Trial: 35306189
Drug: Educational photo
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational photo book about intravenous placement
Trial: 36397219
Drug: Low-dose acupuncture
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose acupuncture (3 times each chemotherapy cycle for a total of 9 times)
Trial: 36397219
Drug: High-dose acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acupuncture (7 times each chemotherapy cycle for a total of 21 times)
Trial: 36397219
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional chemotherapy and antiemetic treatment)
Trial: 35732399
Drug: Intraperitoneal paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal paclitaxel monotherapy, administered through a peritoneal port-a-cath (PAC) system, with 8-16 weekly cycles.
Trial: 34302324
Drug: Anlotinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (12 mg orally once daily for 14 days every 3 weeks)
Trial: 34302324
Drug: Placebo (analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (analogue capsule orally once daily for 14 days every 3 weeks)
Trial: 36306479
Drug: Chemotherapy (carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (carboplatin + paclitaxel or pemetrexed) for 4-6 cycles with optional maintenance pemetrexed
Trial: 34990498
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol 15 mg/kg before treatment (preemptive group, n = 35)
Trial: 34990498
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received intravenous paracetamol 15 mg/kg at the end of treatment (control group, n = 35)
Trial: 33507592
Drug: 750 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/kg/d of standardized extract of Nasturtium officinale (SENO)
Trial: 33507592
Drug: 750 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/kg/d of placebo
Trial: 32159257
Drug: Garlic supplement
RxNorm normalized name: Garlic 300 MG Oral Capsule [GARLIC SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic supplement (500 mg, 2 tablets daily for 8 weeks)
Trial: 32159257
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets daily for 8 weeks)
Trial: 34582088
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy using non-ablative fractional laser and intralesional triamcinolone injection
Trial: 33704569
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser therapy (n = 19)
Trial: 33704569
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser therapy (n = 15)
Trial: 33704569
Drug: Er:YAG +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG + Nd:YAG combination therapy (n = 20)
Trial: 32335288
Drug: Take a
RxNorm normalized name: Take Action
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Take a Break intervention including Motivational Messages, text message Challenge Quizzes, Goal-setting with tobacco treatment specialist, Coping Mini-Games apps, Recognition and Rewards for participation during a 3-week challenge.
Trial: 32335288
Drug: Brief Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Nicotine Replacement Therapy (NRT) sampling and daily smoking assessment text messages for three weeks.
Trial: 32435906
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBM)
Trial: 34537184
Drug: Novel oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel oral anticoagulants (NOACs)
Trial: 34676440
Drug: Methylphenidate (20
RxNorm normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (20 mg, oral)
Trial: 33216002
Drug: Telephone-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based cognitive behavioral therapy (TCBT); n=17 at 3 months and n=13 at 12 months
Trial: 33216002
Drug: Web-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive behavioral therapy (WCBT); n=17 at 3 months and n=12 at 12 months
Trial: 34000119
Drug: Complicated Grief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complicated Grief Treatment (CGT) with placebo
Trial: 33248586
Drug: Feed formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feed formulation with 60% CP soybean meal (SBM)
Trial: 33256621
Drug: Rituximab and
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab and maintenance Mycophenolate mofetil (1200 mg/m2 per day starting 3 months after Rituximab)
Trial: 33256621
Drug: Repeated courses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated courses of prophylactic Rituximab (administered at 0, 8 and 16 months if B cell count normalizes)
Trial: 36325128
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose pistachios (3.0 oz/d; PH)
Trial: 36325128
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose pistachios (1.5 oz/d; PL)
Trial: 36325128
Drug: Pistachios (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistachios (both doses)
Trial: 32045501
Drug: High-dose baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose baclofen (75 mg/day)
Trial: 32045501
Drug: Low-dose baclofen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose baclofen (30 mg/day)
Trial: 36243123
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline injections
Trial: 36379883
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 1g before incision, followed by 125mg/h infusion
Trial: 34448219
Drug: Single 6-mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 6-mm implant with a cantilever (ONE-C)
Trial: 34448219
Drug: Two 6-mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 6-mm implants (TWO)
Trial: 35932397
Drug: SHUTi-OASIS (Internet-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHUTi-OASIS (Internet-delivered cognitive behavioral therapy for insomnia)
Trial: 32959588
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D calcium chewable tablets (0.6 g, once a day) and calcitriol capsules (0.25 μg, three times a day)
Trial: 33141616
Drug: CEE (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE (oral conjugated equine estrogens)
Trial: 33141616
Drug: CEE+MPA (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE+MPA (oral conjugated equine estrogens and medroxyprogesterone acetate)
Trial: 34297008
Drug: Behavioral hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral hypnotic suggestibility
Trial: 36115667
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment with gentamicin (80 mg), vancomycin (1 g), and cefazolin (1 g) dissolved in 500 mL of isotonic saline.
Trial: 36115667
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution of 500 mL isotonic saline.
Trial: 36115667
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment with gentamicin, vancomycin, and cefazolin.
Trial: 36115667
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution of isotonic saline.
Trial: 33452045
Drug: CSCI-furosemide (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSCI-furosemide (average daily dose 125 mg, duration 10 days)
Trial: 32647367
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g whole flaxseed powder
Trial: 32647367
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g hesperidin supplementation
Trial: 32647367
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g flaxseed and 1 g hesperidin (flax‐hes)
Trial: 34246238
Drug: Functional disabilities
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional disabilities in instrumental activities of daily living, self-care activities, and functional mobility
Trial: 32991429
Drug: TPF-based induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF-based induction chemotherapy (IC) regimen
Trial: 32991429
Drug: TP-based induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP-based induction chemotherapy (IC) regimen
Trial: 32991429
Drug: GP-based induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP-based induction chemotherapy (IC) regimen
Trial: 33355063
Drug: Unified protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified protocol for the transdiagnostic treatment of emotional disorders (UP)
Trial: 36425571
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg Nigella sativa (450 mg soft gelatin capsules twice daily for two weeks)
Trial: 36425571
Drug: 2,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 IU of vitamin D3 (1000-IU tablets, two tablets once daily)
Trial: 36425571
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg Nigella sativa and 2,000 IU of vitamin D3 (same dosing as previous groups)
Trial: 36425571
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Nigella sativa and vitamin D3
Trial: 33129356
Drug: Unified protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified protocol for the transdiagnostic treatment of emotional disorders (n = 35)
Trial: 35279873
Drug: GTCs 540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTCs 540 mg plus vitamin C 50 mg
Trial: 35704329
Drug: Licaminlimab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licaminlimab (60 mg/mL, 8 drops/day for 15 days, 4 drops/day for 7 days, then matching vehicle for 7 days)
Trial: 35704329
Drug: Dexamethasone eye
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone eye drops (8 drops/day for 15 days, tapering to 1 drop/day over 14 days)
Trial: 35871917
Drug: Probiotic yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yogurt (100 g daily for 6 weeks)
Trial: 35871917
Drug: Ordinary yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary yogurt (100 g daily for 6 weeks)
Trial: 32918323
Drug: zolpidem extended-release
RxNorm normalized name: zolpidem Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zolpidem extended-release (ER)
Trial: 32711599
Drug: Nanosilver nasal
RxNorm normalized name: Nanosilver
DrugBank: Silver (DB12965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanosilver nasal spray post-surgery
Trial: 32725352
Drug: 0.2% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% bupivacaine infusion via mcTAP catheters
Trial: 32725352
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion via mcTAP catheters (Control)
Trial: 33481452
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia injection followed by ULB in the right eyelid and then in the left (Group A)
Trial: 33481452
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia injection to both eyelids followed by ULB on both eyelids (Group B)
Trial: 32358782
Drug: HRV biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRV biofeedback (HRVB) training, 4-6 weekly sessions until skill acquisition
Trial: 33437991
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy (CST-IT)
Trial: 34148297
Drug: Test cefradine
RxNorm normalized name: cefradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test cefradine capsules (250 mg single dose) under fasting conditions
Trial: 34148297
Drug: Reference cefradine
RxNorm normalized name: cefradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference cefradine capsules (250 mg single dose) under fasting conditions
Trial: 34148297
Drug: Test cefradine
RxNorm normalized name: cefradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test cefradine capsules (250 mg single dose) under fed conditions
Trial: 34148297
Drug: Reference cefradine
RxNorm normalized name: cefradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference cefradine capsules (250 mg single dose) under fed conditions
Trial: 32054486
Drug: TFD containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFD containing 140 mg of caffeine
Trial: 32054486
Drug: TFD containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFD containing 100 mg of caffeine
Trial: 34757657
Drug: Ensartinib (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensartinib (225 mg) after a high-fat, high-calorie meal
Trial: 32826409
Drug: Maternal-administered NICU-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal-administered NICU-based bundle of interventions
Trial: 33413104
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 15 ml (0.25%) ropivacaine on each side
Trial: 34942136
Drug: Risdiplam (5.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risdiplam (5.00 mg for individuals ≥20 kg or 0.25 mg/kg for individuals <20 kg)
Trial: 32094459
Drug: PM2.5 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM2.5 (10 µg/m3 increase in 3-day moving average, lag 0-2)
Trial: 37365436
Drug: Relugolix plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix plus E2 1 mg and NETA 0.5 mg
Trial: 37365436
Drug: Relugolix 40
RxNorm normalized name: relugolix 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix 40 mg alone
Trial: 34410234
Drug: Thoracic spine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic spine manipulation along with conventional physical therapy
Trial: 32824394
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) treatment group
Trial: 34913256
Drug: Negative attitude
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Negative attitude to treatment
Trial: 33057725
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg BID or 10 mg BID
Trial: 35906623
Drug: 61.2 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 61.2 Gy radiation dose with concurrent chemoradiotherapy (paclitaxel/cisplatin regimen for 2 cycles followed by consolidation chemotherapy for 2 cycles)
Trial: 35906623
Drug: 50.4 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50.4 Gy radiation dose with concurrent chemoradiotherapy (paclitaxel/cisplatin regimen for 2 cycles followed by consolidation chemotherapy for 2 cycles)